Evidence map›Paper›PMID 26865601›Full record

Trial reportAnnals of the rheumatic diseases2016

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.

Charles Peterfy, Gerd R Burmester, Vivian P Bykerk, Bernard G Combe, Julie C DiCarlo, Daniel E Furst, Tom W J Huizinga, Dennis A Wong, Philip G Conaghan, Paul Emery

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of the rheumatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01142726 (A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01142726 phase3completednot on this map

A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA

TypeinterventionalSponsorBristol-Myers SquibbRan2010 to 2014Enrolled511ConditionsRheumatoid ArthritisArmsAbatacept, Methotrexate, Abatacept placebo, Methotrexate placebo
3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Co-stimulation Therapy in Rheumatoid Arthritis: Today and Tomorrow.Current treatment options in rheumatology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Charles PeterfySpire Sciences, Inc., Boca Raton, Florida, USA.
Gerd R BurmesterDepartment of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany.
Vivian P BykerkDepartment of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA.
Bernard G CombeDepartment of Rheumatology, Service d'Immuno-Rheumatologie, Montpellier, France.
Julie C DiCarloSpire Sciences, Inc., Boca Raton, Florida, USA.
Daniel E FurstDepartment of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Tom W J HuizingaDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Dennis A WongBristol-Myers Squibb, Princeton, New Jersey, USA.
Philip G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Paul EmeryLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess structural damage progression with subcutaneous abatacept (ABA) in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial following abrupt withdrawal of all rheumatoid arthritis (RA) medication in patients achieving Disease Activity Score (DAS)-defined remission or low disease activity.

methodsPatients with early, active RA were randomised to ABA plus methotrexate (ABA/MTX) 125 mg/week, ABA 125 mg/week or MTX for 12 months. All RA treatments were withdrawn after 12 months in patients with DAS28 (C reactive protein (CRP)) <3.2. Adjusted mean changes from baseline in MRI-based synovitis, osteitis and erosion were calculated for the intention-to-treat population.

results351 patients were randomised and treated: ABA/MTX (n=119), ABA (n=116) or MTX (n=116). Synovitis and osteitis improved, and progression of erosion was statistically less with ABA/MTX versus MTX at month 12 (-2.35 vs -0.68, -2.58 vs -0.68, 0.19 vs 1.53, respectively; p<0.01 for each) and month 18 (-1.34 vs -0.49 -2.03 vs 0.34, 0.13 vs 2.0, respectively; p<0.01 for erosion); ABA benefits were numerically intermediate to those for ABA/MTX and MTX.

conclusionsStructural benefits with ABA/MTX or ABA may be maintained 6 months after withdrawal of all treatments in patients who have achieved remission or low disease activity. TRIAL REGISTRATION NUMBER: NCT01142726; Results.

Indexed as

AbataceptAntirheumatic AgentsArthritis, RheumatoidDisease ProgressionDrug Therapy, CombinationHumansMagnetic Resonance ImagingMethotrexateOsteitisRemission InductionSeverity of Illness IndexSynovitisTreatment OutcomeAbataceptAntirheumatic AgentsMethotrexateInflammationMagnetic ResonaNce ImagingReactive arthritis

Identifiers

PMID26865601
PMCPMC4975847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.